PATROCINADORES CORPORATIVOS
Cursos de otras instituciones
ISTH Webinar · Mutants of Hemostatic Proteins as Potential Therapeutics
27 de mayo de 2022
16:30 h. (horario peninsular España)
Organizado por: International Society on Thrombosis and Haemostasis (ISTH)
Ponentes
- Laurent Mosnier
- Mettine Bos
Event Outline
- Introduction by Dr. Colin Kretz
- Recombinant Factor X Variants as DOAC Antidotes - from Snake Venom to Therapeutic Protein- Mettine Bos, Ph.D. (~20 minutes)
- Engineering of Activated Factor V as Therapy for Severe Bleeding - Super Factor Va- Lauren Mosnier, Ph.D. (~20 minutes)
- Q&A with audience (15 minutes)
Learning Objectives
- Recombinant Factor X Variants as DOAC Antidotes - from Snake Venom to Therapeutic Protein
- Understand the biochemistry and mechanism of action of modifications in factor X(a) to overcome inhibition by factor Xa-inhibiting direct oral anticoagulants
- Learn how a snake venom toxin can form the basis for a factor X-based bypassing agent with therapeutic potential
- Engineering of Activated Factor V as Therapy for Severe Bleeding - Super Factor Va
- Understanding different mechanisms that can contribute to bleeding in settings of Hemophilia, DOACs, and Acute Traumatic Coagulopathy (ATC)
- Learn how engineering of activated Factor V can target the different mechanisms that contribute to bleeding